PharmaCorp Rx Inc. (TSXV:PCRX)
Canada · Delayed Price · Currency is CAD 0.5100
-0.0100 (-1.92%)
At close: Jun 19, 2026
PharmaCorp Rx Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, PharmaCorp Rx stock has a consensus rating of "Strong Buy" and an average price target of $0.67. The average 1-year stock price forecast is 31.37% higher than the current stock price, while the lowest is $0.60 (+17.65%) and the highest is $0.70 (+37.25%).
Price Target: $0.67 (+31.37%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for PharmaCorp Rx stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | May '26 | Jun '26 |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Fred Gatali Raymond James No rating | Raymond James | Buy Initiates $0.70 | Buy | Initiates | $0.70 | +37.25% | Jun 2, 2026 |
Financial Forecast
Revenue This Year
48.48M
from 20.89M
Increased by 132.04%
Revenue Next Year
96.23M
from 48.48M
Increased by 98.49%
EPS This Year
0.01
EPS Next Year
0.03
from 0.01
Increased by 299.85%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CAD.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 51.8M | ||
| Avg | 48.5M | ||
| Low | 41.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 148.0% | ||
| Avg | 132.0% | ||
| Low | 100.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 0.01 | ||
| Low | - |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | 299.9% | |
| Low | - |